AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03680339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: The 100 patients will receive routine ecbolics (for example oxytocin) after delivery of baby plus 400 microgram misoprostol rectally with catheterization and another 400 microgram rectally after closure of abdomen
Study NCT03680339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 10 IU of oxytocin with fetal delivery
Study NCT03065140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training or detraining
Description: A period of detraining or a supervised exercise program.
Study NCT00725712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1363089 (formerly XL880)
Description: c-MET tyrosine kinase inhibitor
Study NCT00598845 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor biopsy study
Description: Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
Study NCT02509949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02509949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02710331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Dronabinol
Description: 10 mg capsule of Dronabinol will be administered orally.
Study NCT02710331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: no alcohol, administered for \~80 minutes.
Study NCT02710331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: no alcohol, administered for \~80 minutes.
Study NCT02710331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Control: Placebo pill (no active cannabinoids) administered orally.
Study NCT02710331 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Placebo pill (no active cannabinoids) administered orally.
Study NCT02710331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ethanol
Description: Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
Study NCT00757224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guidance
Description: Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
Study NCT02960503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
Study NCT02960503 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomized to the control arm (placebo three times a week for 6 months).
Study NCT01367847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Helping the Noncompliant Child (HNC)
Description: Well-established behavioral parent training program (McMahon \& Forehand) for parents of 3 to 8 y.o. children with externalizing problems
Study NCT01367847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-Enhanced Helping the Noncompliant Child (TE-HNC)
Description: Standard HNC program plus technology-enhancements (see description under Arm)
Study NCT03192345 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR439459
Description: Pharmaceutical form: powder for solution for infusion~Route of administration: intravenous infusion
Study NCT03192345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab REGN2810
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous infusion
Study NCT04511624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose1
Description: Drug: IBI112 SC dose1 Drug:placebo
Study NCT04511624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose2
Description: Drug: IBI112 SC dose2 Drug:placebo
Study NCT04511624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose3
Description: Drug: IBI112 SC dose3 Drug:placebo
Study NCT04511624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose4
Description: Drug: IBI112 SC dose4 Drug:placebo
Study NCT04511624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose5
Description: Drug: IBI112 IV dose5 Drug:placebo
Study NCT04511624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose6
Description: Drug: IBI112 SC dose6 Drug:placebo
Study NCT04511624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose7
Description: Drug: IBI112 IV dose7 Drug:placebo
Study NCT03428308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening
Description: Each individual general practitioner reviews his/her record system and detects patients who meet the inclusion criteria. Patients who meet these criteria will be invited to participate in the project.
Study NCT03428308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Patients who are diagnosed with one or more of the selected somatic diseases receive an individualized course of treatment in general practice, primarily focusing on initiation and maintenance of medical treatment, and complying with current clinical guidelines and course programmes. Treatment goals are set in active co-operation with the patient and his/her family and with supervision and support from the Mental Health Centre Copenhagen, clinical pharmacologists and relevant staff from the municipality in terms of contact/support persons.
Study NCT01439386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: PVAI with or without CTI ablation
Study NCT01439386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: CTI ablation only
Study NCT01888874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Description: GLPG0634 capsules.
Study NCT01888874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules.
Study NCT02039076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avatrombopag
Study NCT02858570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenCC-BIO Vaccine
Description: The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.
Study NCT02858570 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined - CRM197
Description: The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
Study NCT03063684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional / Pixel CO2 Laser
Description: The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.~For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application.
Study NCT02001558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microcyn
Description: Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
Study NCT02001558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sterile saline
Description: Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
Study NCT04687163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of 130 mg/m² Oxaliplatin, and 5-fu
Description: Hepatic arterial infusion of 130 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
Study NCT04687163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC of 85 mg/m² Oxaliplatin, and 5-fu
Description: Hepatic arterial infusion of 85 mg/m² oxaliplatin,leucovorin and 2400 mg/m² 5-FU
Study NCT04687163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI
Description: sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)
Study NCT04687163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: sorafenib 400mg bid or lenvatinib 12 mg/day (for bodyweight ≥60 kg) or 8 mg/day (for bodyweight \<60 kg)
Study NCT04128007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast foam 0.3%
Description: experimental
Study NCT04128007 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: experimental
Study NCT03156166 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fiberoptic bronchoscope
Description: Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
Study NCT04394754 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BodyPort
Description: Patients will receive BodyPort, a smart scale that provides advanced cardiac monitoring.
Study NCT04394754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noom
Description: Patients will receive a subscription to use Noom, a personalized diet and weight management application.
Study NCT04394754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversa
Description: patients will receive a subscription to use Conversa, a personalized automated coaching and motivational application.
Study NCT02066675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
Study NCT03785236 — intervention group
Intervention type: RADIATION
Intervention: 68Ga-NODAGA-exendin PET/CT
Description: 68Ga-NODAGA-exendin PET/CT
Study NCT04251611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maintenance of physical exercise
Description: Objectives will be established with the patient to increase the practice of physical exercise and reinforce the control of cardiovascular risk factors (CVRF) and the maintenance of a long-term cardio-healthy lifestyle.
Study NCT01215448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheatgrass juice
Description: 110 CC daily od frozen wheatgrass juice in the intervention arm
Study NCT03491436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iHealth Align
Description: remote monitor glucometer
Study NCT01425905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Blues Program
Study NCT01425905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hey Durham
Study NCT04367480 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Wear placebo TENS device
Study NCT04367480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04367480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04367480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Wear active TENS device
Study NCT01833377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caraway sample
Study NCT01833377 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study NCT02856516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost Glucose Control (A)
Description: Oral nutrition supplement
Study NCT02856516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost Glucose Control (B)
Description: Oral nutrition supplement
Study NCT02856516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Boost Original
Description: Oral nutrition supplement
Study NCT02349997 — intervention group
Intervention type: OTHER
Intervention: no interventions
Description: This is an observational study and no intervention applied.
Study NCT00641680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Study NCT00641680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Study NCT00641680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03651557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL High-dose group
Description: 1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)
Study NCT03651557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL Low-dose group
Description: 1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)
Study NCT03651557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours
Study NCT00863512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00863512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00863512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00863512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT00863512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00863512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: standard follow-up care
Description: Standard care
Study NCT05496153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive posture-balance cardiac rehabilitation exercise
Description: The process of APBCRE consisted of four parts: breathing training and warm-up, aerobic exercise, resistance exercise, and flexibility exercise. The first part lasted for 5-15 minutes, based on balance exercise. The specific steps of balance exercise included stretching of upper limbs, legs, waist, and other parts. And the second part was generally moderate-intensity endurance exercise, thresholding for 60%-75% VO2max/kg metabolic equivalents (METs), 60%-70% maximum heart rate, rating of perceived exertion (RPE) Borg grade 12-13. The exercise duration of this part was usually 30 min. During the self-created APBCRE, the resistance exercise was carried out with the help of the body-building vehicle, and its power was adjusted based on danger assessment level and oxygen uptake at anaerobic threshold. The last part usually lasted for 5-10 min for each-level participants. The total exercise time for one session was generally 50-70 min.
Study NCT02616159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oatmeal
Study NCT02616159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oatmeal
Study NCT00005977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT00005977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00005977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00005977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study NCT03848897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metrology of motor behavior
Description: Biomechanical, physiological, psychological and behavioral analyses
Study NCT00935077 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: PPCM Asthma
Description: Pharmacists collaborate with physicians to manage asthma
Study NCT00935077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24 Month PPCM BP
Description: Pharmacists collaborate with physicians for 24 months to manage hypertension.
Study NCT00935077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 9 Month PPCM BP
Description: Pharmacists collaborate with pharmacists for 9 months to manage hypertension
Study NCT06454643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucloxacillin and gentamicin
Description: This intervention aimed to investigate the effectiveness of administering gentamicin in reducing the incidence of SSI.
Study NCT06454643 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flucloxacillin and ceftriaxone
Description: Control group
Study NCT04769492 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: #ChopViolence/#ChopHIV
Description: Tailored, community-based violence prevention intervention
Study NCT02190123 — intervention group
Intervention type: DRUG
Intervention: ACS patients treated with OAP
Description: Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
Study NCT00084877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00084877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00084877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00084877 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00005977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT03959488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897
Description: Anti-RSV monoclonal antibody with an extended half-life
Study NCT03959488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palivizumab
Description: Approved anti-RSV monoclonal antibody
Study NCT01026818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered by mouth for 9 months
Study NCT01026818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by mouth, daily or on demand for 9 months
Study NCT02834832 — intervention group
Intervention type: DEVICE
Intervention: PECVD coating
Description: SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
Study NCT03088228 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid collection
Study NCT02773420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HET Application
Description: The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
Study NCT00005977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00921635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Description: Blood transfusion to maintain hemoglobin level above 120 g/L
Study NCT00921635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion to maintain hemoglobin level above 100 g/L
Study NCT04211558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod
Study NCT00320697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion + nicotine patch + nicotine gum or lozenges
Description: Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.